Regeneron and Sanofi receive FDA approval of a new once-monthly dosing option for Praluent Injection

Monthly dosing schedule now approved in both US and EU.

Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL cholesterol. The effect of Praluent on cardiovascular (CV) morbidity and mortality has not been determined.

"The FDA approval of once-monthly Praluent is encouraging news for patients with clinical ASCVD or HeFH because it enables physicians to further tailor their treatment to lower LDL cholesterol," said Robert Pordy, ‎Vice President of Cardiovascular & Metabolism Therapeutics, Regeneron. "Selecting the most appropriate therapy based on individual patient preference is an important consideration for healthcare professionals as high cholesterol treatment often requires long-term management."

"Many patients in the US continue to struggle with high levels of bad cholesterol, or LDL cholesterol, despite diet, exercise and other lipid-lowering therapies, so new dosing options are welcome additions to the treatment landscape," said Corinne Hanotin, Global Project Head, Cardiovascular Clinical Development, Sanofi. "Praluent is now the only PCSK9 inhibitor to offer two dosage strengths with two levels of efficacy, as well as a monthly dosing option."

The 300 mg dose is administered via two 150 mg injections at two different injection sites. Each 1 mL pre-filled pen delivers 150 mg of Praluent in 20 seconds or less. The European Commission (EC) also approved the monthly 300 mg dose of Praluent in November 2016.

The once-monthly dose of Praluent was approved by the FDA and the EC based on results from the Phase III ODYSSEY CHOICE I study, which evaluated the efficacy and safety of Praluent 300 mg every 4 weeks compared to placebo in patients with hypercholesterolemia who were also taking concomitant statin. In the US, the recommended starting dose for Praluent is 75 mg once every 2 weeks administered subcutaneously, or alternatively, 300 mg once every 4 weeks (monthly) for patients who prefer less frequent dosing. These doses can be adjusted to a maximum dose of 150 mg every 2 weeks for patients requiring greater LDL cholesterol reductions.

Praluent is contraindicated in patients with a history of a serious hypersensitivity reaction to Praluent. Allergic reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization. In the ODYSSEY CHOICE I study in which all patients received an injection of Praluent or placebo every 2 weeks to maintain the blind, local injection site reactions were reported more frequently in patients treated with Praluent 300 mg every 4 weeks as compared to those receiving Praluent 75 mg every 2 weeks or placebo (16.6%, 9.6%, and 7.9%, respectively).